Tonix Shutters MDD Candidate After Phase II Miss
Executive Summary
Tonix’s once-daily formulation of tianeptine, widely used to treat depression in Europe, failed to improve depression severity in a Phase II study and will be discontinued, the latest R&D setback for the biotech.